Andrea Alimonti

Head of the Molecular Oncology Laboratory of the Institute of Oncology Research and of the Molecular Oncology Laboratory of the Veneto Institute of Molecular Medicine, Full Professor of Oncology at Università della Svizzera italiana, Full Professor of Pharmacology at Università degli Studi di Padova, Full Professor of Experimental Oncology and Translational Cancer Medicine at ETH Zurich

Full biography

Graduated from the Sapienza University of Rome, Andrea Alimonti completed his studies in clinical oncology at the Regina Elena National Cancer Institute, in Rome.
He then continued his education in the United States, first at the Memorial Sloan-Kettering Cancer Center in New York and then at the Harvard Medical School in Boston, where he worked in the Pandolfi Laboratory, a cutting-edge cancer research institute.
Prof. Alimonti is currently Head of the Molecular Oncology Laboratory of the Institute of Oncology Research – IOR (affiliated with Università della Svizzera italiana) in Bellinzona and of the Molecular Oncology Laboratory of the Veneto Institute of Molecular Medicine in Padova (affiliated with Università degli Studi di Padova), Full Professor of Oncology at Università della Svizzera italiana, of Pharmacology at Università degli Studi di Padova, and of Experimental Oncology and Translational Cancer Medicine at ETH Zurich.

His research is focused on the characterization of a novel type of cellular senescence response which is elicited by complete loss of the tumor suppressor PTEN, and on the identification of novel compounds with pro-senescence activity.
His final aims are: to develop the concept of pro-senescence therapy for cancer, from experimental evidence to the clinic, investigating the efficacy of “pro-senescence” compounds in phase I clinical trials; to combine pro-senescence therapy with other drugs to enhance the anti-tumor activity of the immune system; to identify senescence markers in human tumor samples to be used clinically.

"I have been a member of IBSA Foundation's Scientific Board for many years. IBSA Foundation's call for fellowships has become well renowned over time and the number and quality of the applicants has increased. IBSA Foundation's annual special forums are important events where the top notch scientists in the world explain their fundamental discoveries to a very large audience.
I am therefore very proud to be a part of all this."

Andrea AlimontiHead of the Molecular Oncology Laboratory of the Institute of Oncology Research and of the Molecular Oncology Laboratory of the Veneto Institute of Molecular Medicine, Full Professor of Oncology at Università della Svizzera italiana, Full Professor of Pharmacology at Università degli Studi di Padova, Full Professor of Experimental Oncology and Translational Cancer Medicine at ETH Zurich